Barclays PLC Sells 509,134 Shares of Grifols, S.A. (NASDAQ:GRFS)

Barclays PLC decreased its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 85.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 83,418 shares of the biotechnology company's stock after selling 509,134 shares during the period. Barclays PLC's holdings in Grifols were worth $621,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Grifols in the fourth quarter valued at $14,434,000. JPMorgan Chase & Co. raised its stake in shares of Grifols by 144.0% in the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock valued at $17,782,000 after buying an additional 1,181,959 shares during the period. Brandes Investment Partners LP raised its stake in shares of Grifols by 3.0% in the fourth quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock valued at $152,491,000 after buying an additional 592,096 shares during the period. Legal & General Group Plc raised its stake in shares of Grifols by 159.5% in the fourth quarter. Legal & General Group Plc now owns 329,953 shares of the biotechnology company's stock valued at $2,453,000 after buying an additional 202,796 shares during the period. Finally, Highland Peak Capital LLC raised its stake in shares of Grifols by 29.5% in the fourth quarter. Highland Peak Capital LLC now owns 786,210 shares of the biotechnology company's stock valued at $5,849,000 after buying an additional 179,114 shares during the period.

Grifols Stock Performance

Shares of NASDAQ:GRFS traded up $0.63 during midday trading on Monday, reaching $7.73. 1,467,089 shares of the company traded hands, compared to its average volume of 1,189,231. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 12 month low of $5.79 and a 12 month high of $9.96. The firm has a market capitalization of $5.31 billion, a price-to-earnings ratio of 6.65 and a beta of 0.44. The firm's fifty day moving average price is $7.34 and its two-hundred day moving average price is $7.65.

Analyst Ratings Changes

Separately, Morgan Stanley initiated coverage on Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.